Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name Amivantamab-vmjw
Trade Name Rybrevant
Synonyms JNJ-61186372
Drug Descriptions

Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, in combination with carboplatin and pemetrexed as first-line therapy for adult patients with NSCLC harboring EGFR exon 20 insertion mutations and for patients harboring EGFR exon 19 deletion or L858R who progressed on prior EGFR TKI, and in combination with Lazcluze (lazertinib) as first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov).

DrugClasses EGFR Antibody 60 MET Antibody 31
CAS Registry Number 2171511-58-1
NCIT ID C124993

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Amivantamab-vmjw Amivantamab-vmjw 0 11
Amivantamab-vmjw + Bevacizumab + Lazertinib Amivantamab-vmjw Bevacizumab Lazertinib 0 1
Amivantamab-vmjw + Brigatinib Amivantamab-vmjw Brigatinib 0 0
Amivantamab-vmjw + Capmatinib Amivantamab-vmjw Capmatinib 0 1
Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Carboplatin Lazertinib Pemetrexed Disodium 0 3
Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw Carboplatin Pemetrexed Disodium 0 4
Amivantamab-vmjw + Cetrelimab Amivantamab-vmjw Cetrelimab 0 1
Amivantamab-vmjw + Dexamethasone + Lazertinib Amivantamab-vmjw Dexamethasone Lazertinib 0 1
Amivantamab-vmjw + Docetaxel Amivantamab-vmjw Docetaxel 0 1
Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw Fluorouracil Irinotecan Leucovorin 0 1
Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin Amivantamab-vmjw Fluorouracil Leucovorin Oxaliplatin 0 1
Amivantamab-vmjw + Lazertinib Amivantamab-vmjw Lazertinib 0 7
Amivantamab-vmjw + Lazertinib + Methotrexate Amivantamab-vmjw Lazertinib Methotrexate 0 1
Amivantamab-vmjw + Lazertinib + Montelukast Amivantamab-vmjw Lazertinib Montelukast 0 1
Amivantamab-vmjw + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Lazertinib Pemetrexed Disodium 0 1
Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Lazertinib rHuPH20 0 1
Amivantamab-vmjw + Osimertinib Amivantamab-vmjw Osimertinib 0 1
Amivantamab-vmjw + Paclitaxel Amivantamab-vmjw Paclitaxel 0 1
Amivantamab-vmjw + Pembrolizumab Amivantamab-vmjw Pembrolizumab 0 1
Amivantamab-vmjw + rHuPH20 Amivantamab-vmjw rHuPH20 0 1
Amivantamab-vmjw + Tepotinib Amivantamab-vmjw Tepotinib 0 1


Additional content available in CKB BOOST